British manufacturing company Thesis Technology has announced that the foot model in its LimbO Waterproof Protector range is now available on FP10 prescription. 

The product has been designed for patients with chronic foot wounds, including diabetic foot ulcers, who need to keep their foot dressings dry in the shower and require a reliable and comfortable solution.

The LimbO foot model, which has been accepted on the Drug Tariff for England and Wales, is a class I medical device first developed by Thesis Technology eight years ago.

Its design incorporates a non-constrictive neoprene seal. The waterproof cover is available in two sizes and is latex free, meaning it is simple and safe to use by patients with sensitive skin or compromised blood flow, which can be a major issue for patients living with diabetes.

Adrian Coleman, sales and marketing director at Thesis Technology, said: "We're excited about extending our range of LimbO waterproof protectors on the drug tariff and being able to help more patients keep their foot dressings dry. The foot model has rapidly become one of our most popular LimbOs, partly because it helps a large patient group that is growing exponentially year on year - those living with diabetes for which a high proportion have foot complications. In time we expect the LimbO foot model to match the popularity of our half leg LimbOs and elbow LimbOs (for PICC lines) which are also on FP10 prescription. 

"Over the last 15 years, our team have worked hard to establish the LimbO adult half leg options on prescription. These models have become the most popular waterproof solution for UK prescribers for patients with lower leg venous ulcers or wounds. Our LimbO range now accounts for 75% of waterproof protector options on the Drug Tariff and this is set to rise with the addition of the LimbO foot model. We're very proud that our product helps so many patients maintain their independence during recovery, contributing to their quality of life."